Advicenne Inc. is the US arm of Advicenne S.A., a Publicly traded French pharmaceutical Company developing Pathbreaking treatments for rare diseases. Our focus in the US is the clinical program for ADV7103. ADV7103 is an investigational drug designed to treat distal renal tubular acidosis (dRTA) in patients of all ages. ADV7103 is also being developed for the treatment of a second indication, cystinuria, an inherited renal tubulopathy.